170569-23-0

Basic information

• Product Name: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-methylphenyl)-, ethyl ester
• CAS NO: 170569-23-0
• Molecular Formula: C19H19N3O4S
• Molecular Weight: 385.444
• Mol File: 170569-23-0.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-methylphenyl)-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-methylphenyl)-, ethyl ester(170569-23-0)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxylic acid, 1-[4-(aminosulfonyl)phenyl]-5-(4-methylphenyl)-, ethyl ester(170569-23-0)

Safety Data

• Hazardous Substances Data: 170569-23-0(Hazardous Substances Data)

Upstream product

• 5814-37-9 ethyl-4-(4-methylphenyl)-2,4-dioxobutyrate 
• 17852-52-7 4-hydrazinobenzene-1-sulfonamide hydrochloride 
• 113503-90-5 2-hydroxy-4-oxo-4-p-tolylbut-2-enoic acid ethyl ester 
• 4392-54-5 4-aminosulfonylphenylhydrazine 
• 122-00-9 para-methylacetophenone 
• 63-74-1 sulfanilamide 
• 113503-90-5 ethyl 2-hydroxy-4-oxo-4-(4-methylphenyl)-2-butenoate 

Downstream Products

• 850829-08-2 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid 
• 641639-48-7 4-(3-(hydroxymethyl)-5-(p-tolyl)-1H-pyrazol-1-yl)benzenesulfonamide 
• 850829-14-0 4-(3-formyl-5-p-tolyl-pyrazol-1-yl)-benzenesulfonamide 
• 1287761-20-9 (E)-3-[1-(4-sulfamoylphenyl)-5-p-tolyl-1H-pyrazol-3-yl]-acrylic acid ethyl ester 
• 1287761-21-0 3-[1-(4-sulfamoylphenyl)-5-p-tolyl-1H-pyrazol-3-yl]-propionic acid ethyl ester 
• 1287761-22-1 4-[3-(3-hydroxypropyl)-5-p-tolyl-pyrazol-1-yl]-benzenesulfonamide 
• 1287761-23-2 4-{3-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-5-p-tolyl-pyrazol-1-yl}-benzenesulfonamide 
• 1287761-24-3 C₁₉H₂₂N₄O₂S 
• 1287760-95-5 4-(5-p-tolyl-3-{3-[3-(3-trifluoromethylphenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide 
• 960215-02-5 3-[1-(4-sulfamoylphenyl)-5-p-tolyl-1H-pyrazol-3-yl]propanoic acid 

Relevant articles and documents

Synthesis, biological evaluation and in silico modelling studies of 1,3,5-trisubstituted pyrazoles carrying benzenesulfonamide as potential anticancer agents and selective cancer-associated hCA IX isoenzyme inhibitors

Inhibition of carbonic anhydrases (CAs, EC 4.2.1.1) has clinical importance for the treatment of several diseases. They participate in crucial regulatory mechanisms for balancing intracellular and extracellular pH of the cells. Among CA isoforms, selectiv

New selective carbonic anhydrase IX inhibitors: Synthesis and pharmacological evaluation of diarylpyrazole-benzenesulfonamides

Carbonic anhydrase (CA) IX expression is increased upon hypoxia and has been proposed as a therapeutic target since it has been associated with poor prognosis, tumor progression and pH regulation. We report the synthesis and the pharmacological evaluation

CYP2C9 structure-metabolism relationships: Optimizing the metabolic stability of COX-2 inhibitors

The cytochrome P450 (CYP) family is composed of a large group of monooxygenases that mediate the metabolism of xenobiotics and endogenous compounds. CYP2C9, one of the major isoforms of the CYP family, is responsible for the phase I metabolism of a variety of drugs. The aim of the present investigation is to use rational design together with MetaSite, a metabolism site prediction program, to synthesize compounds that retain their pharmacological effects but that are metabolically more stable in the presence of CYP2C9. The model compound for the study is the nonsteroidal anti-inflammatory drug celecoxib, a COX-2 selective inhibitor and known CYP2C9 substrate. Thirteen analogs of celecoxib were designed, synthesized, and evaluated with regard to their metabolic properties and pharmacologic effects. The docking solutions and the predictions from MetaSite gave useful information leading to the design of new compounds with improved metabolic properties.